Live Breaking News & Updates on Fibrogen Shareholder Class Action Lawsuit

Stay updated with breaking news from Fibrogen shareholder class action lawsuit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Capula Management Ltd Invests $439,000 in FibroGen, Inc. (NASDAQ:FGEN)

Capula Management Ltd purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 23,520 shares of the biopharmaceutical company’s stock, valued at approximately $439,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes […] ....

United States , Benjamin Cravatt , Jamesa Schoeneck , Raymond James , William Blair , Stifel Nicolaus , Fibrogen Inc , Securities Exchange Commission , Pricet Rowe Associates Inc , Hermes Inc , Norges Bank , Holdings Channel , Capula Management Ltd , Free Report , Pictet Asset Management , Asset Management , Director Benjamin Cravatt , Exchange Commission , Director James , Visit Holdingschannel , Fibrogen Daily , Nasdaq Fgen , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Q3 2023 EPS Estimates for FibroGen, Inc. (NASDAQ:FGEN) Cut by Analyst

FibroGen, Inc. (NASDAQ:FGEN – Free Report) – Investment analysts at William Blair lowered their Q3 2023 earnings estimates for shares of FibroGen in a research note issued on Tuesday, August 8th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.72) per share for the quarter, down from their previous estimate […] ....

United States , Jamesa Schoeneck , Stifel Nicolaus , Raymond James , William Blair , Blackrock Inc , Fibrogen Inc , Vanguard Group Inc , Fibrogen Company Profile , Schroder Investment Management Group , Free Report , Thane Wettig , Director James , Street Corp , Investment Management Group , Get Free Report , Fibrogen Daily , Nasdaq Fgen , Earnings Estimates ,

FibroGen (NASDAQ:FGEN) Rating Lowered to Underperform at Bank of America

FibroGen (NASDAQ:FGEN – Get Free Report) was downgraded by analysts at Bank of America from a “neutral” rating to an “underperform” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $2.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $4.00. Bank of […] ....

United States , Stifel Nicolaus , Raymond James , William Blair , Benjamin Cravatt , Vanguard Group Inc , Blackrock Inc , Securities Exchange Commission , Hermes Inc , Fibrogen Inc , Get Free Report , Marketbeat Ratings , Thane Wettig , Exchange Commission , Director Benjamin Cravatt , Street Corp , Federated Hermes , Fibrogen Daily , Nasdaq Fgen , Bank Of America Co ,

Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation?

Key Insights FibroGen's estimated fair value is US$2.48 based on 2 Stage Free Cash Flow to Equity Current share price. ....

United States , For Fibrogen , High Quality Alternatives , Discounted Cash Flow , Free Cash Flow , Uture Cash Flows , Ntrinsic Value , Erminal Value , Resent Value ,

FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. ....

Key Company Metrics For Fibrogen , Zacks Investment Research , Zacks Consensus Estimate , Wall Street , Key Company Metrics , Zacks Rank , Zacks Investment , All Street Analysts , Reported Number ,